PI3Kα-IN-4 (C09-1164-027)

PI3Kα-IN-4 is a potent, selective and orally active inhibitor of PI3Kα , with an IC 50 of 1.8 nM. PI3Kα-IN-4 has antitumor activityIn VitroPI3Kα-IN-4 (compound 10) inhibits PI3Kα, β, δ, and γ, with IC 50 s of 1.8, 271.0, 13.9, and 13.8 nM, respectively in kinase assays. PI3Kα-IN-4 inhibits PI3Kα, β, δ, and γ, with IC 50 s of 12.1,1393, 183, and >10000 nM, respectively in cell based assays. MCE has not independently confirmed the accuracy of these methods. They are for reference only.In VivoPI3Kα-IN-4 (compound 10) (30 mg/kg; p.o. once daily for 21 d) achieves the best efficacy, which could inhibit tumor growth by 73.0% in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily for 30 d) dose dependently suppresses tumor growth by 62.5% (15 mg/kg), 86.0% (30 mg/kg) and 90.7% (40 mg/kg), respectively in mice . PI3Kα-IN-4 (15-40 mg/kg; p.o. once daily; 1-4 h) inhibits the phosphorylation of Akt in a dose- and time-dependent manner in vivo . PI3Kα-IN-4 shows high C max (mouse 22167, rat 2327 nM) and good bioavailability (mouse 59.4%, rat 46.9%) following oral administration (mouse 10, rat 3 mg/kg) . PI3Kα-IN-4 shows t 1/2 (mouse 0.99, rat 1.22 h) and low plasma clearance (mouse 4.16, rat 5.28 mL/min/kg) following intravenous injection (mouse 1, rat 1 mg/kg) . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: BT-474 subcutaneous xenograft mice Dosage: 30 mg/kg Administration: P.o. once daily for 21 days Result: Inhibited tumor growth by 73.0% and could be tolerated.Form:SolidIC50& Target:PI3Kα 1.8 nM (IC 50 ). Specification: 0.99 Molecular Formula: C25H23ClFN5O5S Molecular Weight: 560